Fewer than half of high-risk patients with atrial fibrillation (AF) receive recommended anticoagulation therapy for stroke prevention, and of those who start anticoagulation, 30% – 50% stop treatment within 12 months. Shared decision-making (SDM) can improve adherence to anticoagulant therapy and should be used to individualize anticoagulant therapy based on each patient’s risk of stroke and bleeding and personal preferences.
The final installment of this CME Outfitters BriefCase series focuses on patient education and SDM when providing care via telemedicine, including use of digital decision aids and electronic resources to assist with SDM, developing individualized treatment plans, overcoming social health care disparities, building trust with patients in a virtual care setting, and reinforcing the importance of adherence and persistence to prescribed therapy.
At the end of this CME/CE activity, participants should be able to utilize digital decision aids for patient education and SDM when providing care via telemedicine.
The following learning objectives pertain only to those requesting CNE or CPE credit: Explain digital decision aids for patient education and SDM for care via telemedicine.
Supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.
Primary care physicians, cardiologists, PAs, nurse practitioners, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Turakhia reports that he receives grants from the American Heart Association; Apple Inc.; Bayer; Boehringer Ingelheim; Bristol Myers Squibb Company; Cardiva Medical, Inc.; Janssen Pharmaceuticals, Inc.; and SentreHEART, Inc. He is a consultant for Abbott; BIOTRONIK, Inc.; Cardiva Medical, Inc.; iRhythm Technologies, Inc.; Johnson & Johnson; Medtronic; Milestone Pharmaceuticals, Inc.; MyoKardia, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; and Sanofi. He receives other financial or material support as an editor for JAMA Cardiology.
Dr. Tarakji reports that he is a consultant for AliveCor, Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; and Medtronic.
Dr. Savoy has no disclosures to report.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-112-H01-P